Hong Kong Stock Concept Tracking | First Government-Priced Brain-Computer Interface Surgery Conducted in Wuhan; Institutions Optimistic About Accelerated Commercialization (Including Related Stocks)

China's first government-priced brain-computer interface (BCI) surgery was recently performed in Wuhan, Hubei, marking the formal inclusion of implantable BCI technology into the standardized medical service system. On November 26, at Tongji Hospital affiliated with Huazhong University of Science and Technology, a 31-year-old spinal cord injury patient underwent invasive BCI device implantation, becoming the first case in China to follow government-approved medical service pricing. The implantation cost was 6,552 yuan, covered by research funding.

From December 4 to 5, 2025, the "2025 Brain-Computer Interface Conference" was successfully held in Shanghai under the theme "Connecting Brains, Gathering Intelligence in Shanghai." Fu Xiaofeng, Deputy Director of the Fifth Department of the Ministry of Science and Technology, stated that the ministry will continue supporting BCI innovation and future industry development, strengthening core technology breakthroughs, expanding application scenarios, and fostering industry chain collaboration to create a favorable innovation ecosystem.

CITIC Securities noted that some BCI companies have upgraded their product channels or plan to submit Class III medical device registrations. With strong policy support from central and local governments, clinical and commercial applications are expected to accelerate, increasing investment opportunities. Rising valuations of BCI-related listed companies this year may boost financing activity in the primary market and reshape valuations, creating synergy between capital and industry growth. The firm recommends focusing on companies with strong R&D capabilities, deep collaborations with leading research institutions, or investments in prominent BCI startups.

Dongwu Securities believes domestic policies and global clinical progress will drive the BCI industry forward. Huafu Securities highlighted that advancements in brain science, AI, medicine, and cognitive neuroscience are expanding BCI's scope. China holds multiple advantages in BCI development, with a complete industry chain covering upstream (materials, chips, electrodes), midstream (signal acquisition and processing), and downstream (healthcare, consumer applications, industrial use).

Related Hong Kong-listed BCI stocks include: Brainhole Technology (06681), NANJING PANDA (00553), MICROPORT NEURO (02172), and HEARTCARE-B (06609).